+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Safety and efficacy of single-dose fluconazole compared with a 7-day regimen of itraconazole in the treatment of AIDS-related oropharyngeal candidiasis



Safety and efficacy of single-dose fluconazole compared with a 7-day regimen of itraconazole in the treatment of AIDS-related oropharyngeal candidiasis



Journal of International Medical Research 26(3): 159-170



The primary aim of this study was to compare the efficacy and safety of single-dose fluconazole and a 7-day regimen of itraconazole for the treatment of oropharyngeal candidiasis in human immunodeficiency virus (HIV)-positive patients. In this open-label trial, 40 HIV-positive patients with oropharyngeal candidiasis were randomized to receive either one dose of fluconazole 150 mg or seven daily doses of itraconazole 100 mg. Clinical condition was assessed at baseline, day 8, and day 30 (follow-up). In the fluconazole group, 15 of 20 (75%) patients were clinically cured on day 8, three (15%) were clinically improved, and two (10%) were treatment failures. At follow-up, six (30%) patients experienced relapse. In the itraconazole group, four of 17 (24%) patients were clinically cured at 8 days, and two (12%) were clinically improved; two patients relapsed by day 30. Ten (50%) patients in the itraconazole group were taking concomitant medications that could potentially affect the bioavailability of itraconazole. After excluding the results from these patients, clinical response rates remained significantly higher in the fluconazole treatment arm. These results suggest that a single 150-mg dose of fluconazole may be a safe, effective, and convenient therapy for acquired immune deficiency syndrome-related oropharyngeal candidiasis. The lower response rate in the patients who received itraconazole 100 mg daily for 7 days could be explained by drug interactions and the unpredictable absorption of itraconazole.

(PDF emailed within 1 workday: $29.90)

Accession: 003264505

Download citation: RISBibTeXText

PMID: 9718471


Related references

An open multicentre comparative study of the efficacy, safety and tolerance of fluconazole and itraconazole in the treatment of cancer patients with oropharyngeal candidiasis. European Journal of Cancer 40(9): 1314-1319, 2004

Evaluation of efficacy and safety of itraconazole oral solution for the treatment of oropharyngeal candidiasis in aids patients. Brazilian Journal of Infectious Diseases 5(2): 60-66, 2001

A double-blind comparison of itraconazole oral solution and fluconazole capsules for the treatment of oropharyngeal candidiasis in patients with AIDS. Clinical Infectious Diseases 26(6): 1368-1373, 1998

Efficacy and safety of single dose fluconazole in the treatment of vaginal candidiasis. Investigacion Medica Internacional 17(4): 181-184, 1991

Efficacy and safety of a single oral 150 mg dose of fluconazole for the treatment of vulvovaginal candidiasis in Japan. Journal of Infection and ChemoTherapy 21(7): 520-526, 2016

An open multicentre study of the efficacy and safety of a single dose of fluconazole 150 mg in the treatment of vaginal candidiasis in general practice. British Journal of Clinical Practice 44(6): 219-222, 1990

Fluconazole compared with itraconazole in the treatment of esophageal candidiasis in AIDS patients: a double-blind, randomized, controlled clinical study. Scandinavian Journal of Infectious Diseases 27(6): 613-617, 1995

Itraconazole solution for fluconazole-refractory oropharyngeal candidiasis in AIDS Correlation of clinical response with in vitro susceptibility. TENTH INTERNATIONAL CONFERENCE ON AIDS, INTERNATIONAL CONFERENCE ON STD Tenth International Conference on AIDS and the International Conference on STD, Vol 2; The global challenge of AIDS: Together for the future : 2) 23, 1994

Itraconazole cyclodextrin solution for fluconazole-refractory oropharyngeal candidiasis in AIDS: correlation of clinical response with in vitro susceptibility. Aids 10(12): 1369-1376, 1996

Itraconazole oral solution versus fluconazole treatment of oropharyngeal candidiasis. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 35(0): 244, 1995

Single dose fluconazole versus 7 days itraconazole for treatment of oral candidiasis in HIV patients A prospective randomized study. Program & Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 33(0): 267, 1993

Fluconazole 150 mg single dose versus itraconazole 200 mg per day for 3 days in the treatment of acute vaginal candidiasis: a double-blind randomized study. European Journal of Obstetrics and Gynecology and Reproductive Biology 106(2): 193-197, 2003

Treatment of fluconazole-refractory oropharyngeal candidiasis with itraconazole oral solution in HIV-positive patients. Aids Research and Human Retroviruses 15(16): 1413-1417, 1999

Itraconazole suspension in the treatment of HIV-infected patients with fluconazole-resistant oropharyngeal candidiasis and esophagitis. Mycoses 39 Suppl 1: 102-106, 1996

Itraconazole and fluconazole in oropharyngeal candidiasis. Annals of Dentistry 52(2): 12-16, 1993